Polymorphism of vascular endothelial growth factor -1154G>A (rs1570360) with cancer risk: a meta-analysis of 16 case-control studies.

ABSTRACT

Published data on the association of vascular endothelial growth factor (VEGF) -1154G>A polymorphism with cancer risk is inconclusive. To derive a more precise estimation of association between VEGF -1154G>A polymorphism and the risk of cancer, we performed a meta-analysis of 7,071 cancer cases and 7,693 controls from 16 published case-control studies. Our meta-analysis didn't reveal an association between VEGF -1154G>A polymorphism and overall cancer risk (GG vs. AA OR 1.08, 95% CI 0.96-1.20; GA vs. AA OR 1.04, 95% CI 0.93-1.17; recessive model GG+GA vs. AA OR 1.06, 95% CI 0.95-1.18; dominant model GG vs. GA+AA, OR 1.11, 95% CI 1.00-1.24). Nevertheless, for non-Caucasians, GG homozygote may have higher cancer risk compared with either A carriers (OR 1.58, 95% CI 1.12-2.23) or AA homozygote (OR 1.43, 95% CI 1.17-1.76). No significant heterogeneity was detected except in the dominant model and "prostate cancer" subgroup analysis. More studies with larger samples are warranted to confirm these findings.